Cocrystal Pharma's CDI-988 oral norovirus inhibitor to be featured at ICAR 2026

Cocrystal Pharma, Inc.

CDI-988 is the first oral antiviral drug candidate developed for prevention and treatment of norovirus infections.
Company to present Phase 1b challenge study data at ICAR 2026 in Prague (Apr 27-May 1, 2026).
No approved antiviral therapies or vaccines for norovirus; estimated $10.6B annual US economic burden.
CDI-988 is a pan-viral protease inhibitor also targeting coronaviruses, developed using proprietary structure-based platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.